Research
Hormonal
Acetate, a primary SCFA, crosses the blood-brain barrier to directly stimulate the hypothalamic arcuate nucleus, increasing POMC (anorexigenic) and decreasing AgRP (orexigenic) neuron expression.
Ensure adequate intake of fermentable fibers to generate acetate. While the direct brain effect is confirmed in animals, the practical application relies on the cumulative effect of high fiber intake.
ModerateSupportsMEDIUM confidence
peripheral acetate was taken up by the hypothalamus in greater amounts than other brain tissues and it was found that within the hypothalamus acetate promotes an anorectic signal in the ARC, leading to increased POMC and reduced agouti-related peptide neuron expression.
Why this rating
Based on PET/CT studies in mice; human translation is plausible but less directly quantified in terms of behavioral outcome in this review.
Source
Control of appetite and energy intake by SCFA: what are the potential underlying mechanisms?
Edward S. Chambers et al. · Proceedings of The Nutrition Society · 2014
DOI 10.1017/s0029665114001657
narrative_reviewCited 338×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Elevated colonic production of short-chain fatty acids (SCFA) via fermentable dietary fiber intake suppresses appetite and energy intake by stimulating the release of anorectic hormones PYY and GLP-1 through FFAR2 receptor activation on colonic L-cells.Moderate
- Propionate metabolism in the liver stimulates hepatic gluconeogenesis, which activates hepatic vagal afferents to signal satiety to the brainstem, a mechanism well-established in ruminants but less defined in humans.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →